Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights

- On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 - - First Presentations of Preclinical Data with GTx-mAb Development Candidate HMI-104 for PNH, and... | May 11, 2023

Related Keywords

United States ,Cara Mayfield ,Albert Seymour ,Slattery Jr ,Oxford Biomedica ,American Society Of Gene Cell Therapy ,Exchange Commission ,Corporate Communications ,Nasdaq ,Company Contacts ,Homology Medicines Inc ,Securities Exchange ,Pfizer ,World Orphan Drug Congress United States ,Globenewswire Inc ,Company Stock Purchase Agreement ,Report Initial Clinical Data ,Editing Trial ,Preclinical Data ,Financial Position ,Anticipated Cash Runway ,Fourth Quarter ,Chief Executive Officer ,Cell Therapy ,Annual Meeting ,Stock Purchase Agreement ,Orphan Drug Congress United States ,Homology Medicines ,Securities Act ,Securities Exchange Act ,Quarterly Report ,Tables Follow ,Nc Stock Exchange ,News ,Information ,Press Release ,N ,Track ,O ,Report ,Nitial ,Linical ,Data ,Rom ,Heedit ,Oku ,Gene ,Editing ,023 ,First ,Presentations ,F ,Reclinical ,Ith ,Development ,Candidate ,Or Fixx Us4380831077 ,